SCHEMBL5216692

SCHEMBL5216692

COc1cccc(-n2cc(-c3cnc4ccccc4n3)cn2)c1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 14/20 0.57
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
RAB9A P51151 1/20 0.52
MKNK2 Q9HBH9 3/20 0.51
KCNH2 Q12809 1/20 0.50
GRM4 Q14833 1/20 0.50
FGFR3 P22607 3/20 0.48
KDR P35968 3/20 0.48
FGFR1 P11362 2/20 0.48
FGFR2 P21802 2/20 0.48
FGFR4 P22455 2/20 0.48
NMT1 P30419 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216715 0.88 ALDH1A1 (0.48) MKNK1NPC1ALDH1A1MAPTRAB9A
SCHEMBL5219136 0.88 NPC1 (0.50) MKNK1NPC1ALDH1A1MAPTRAB9A
SCHEMBL5216682 0.85 FGFR1 (0.49) MKNK1NPC1MAPTRAB9AGRM4
SCHEMBL5218314 0.84 GRM4 (0.54) MKNK1NPC1MAPTRAB9AMKNK2
SCHEMBL5216495 0.83 GRM4 (0.54) NPC1MAPTRAB9AKCNH2GRM4
SCHEMBL5217700 0.82 NPC1 (0.45) MKNK1NPC1RAB9AKCNH2GRM4
SCHEMBL5217224 0.82 MKNK1 (0.52) MKNK1NPC1ALDH1A1MAPTRAB9A
SCHEMBL8353703 0.82 BCHE (0.51) NPC1ALDH1A1MAPTRAB9AKCNH2
SCHEMBL5216133 0.82 GRM5 (0.42) MKNK1NPC1MAPTRAB9AKCNH2
SCHEMBL30795888 0.81 GRM5 (0.64) MKNK1MKNK2KCNH2GRM4NMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C MKNK1 893/4885NPC1 4205/4885ALDH1A1 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.